FDA expands endometrial cancer indication for GSK’s Jemperli

The US Food and Drug Administration (FDA) yesterday approved Jemperli (dostarlimab-gxly), from UK pharma major GSK (LSE: GSK), with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC).

Dostarlimab-gxly was previously approved in 2021 with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent EC that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).

Sales expectations